Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic – World Health Organization

by | Nov 11, 2022 | COVID-19

Overview
Leishmaniasis continues to be a major
health problem in 4 eco-epidemiological
regions of the world: the Americas, East
Africa, North Africa and West and South-east Asia. This global report on leishmaniasis surveillance updates those published in 2016, 2018 and 2021. Six indicators of leishmaniasis are publicly available through the
Global Health Observatory (GHO). In addition, country profiles of up to 30 indicators
are published, with detailed data received
from 45 Member States. The aims of this report are to update the
results of the GHO leishmaniasis indicators reported by Member States to WHO
up to 2021, to describe specific indicators
of gender and age distribution, relapses,
the AmBisome® donation programme,
selected outbreaks, case fatality rates for
visceral leishmaniasis (VL, also known as
kala-azar), rates of co-infection with HIV
and VL and the burden of post-kala-azar
dermal leishmaniasis (PKDL). This report
also describes the Kala-azar Elimination
Programme in South-East Asia and
adverse events after administration of
antileishmanial drugs.

Article Attribution | Read More at Article Source

Share This